logo
Plus   Neg
Share
Email

Vodafone Group Partners With OFT To Launch Vodafone Brand In Oman

Vodafone Group (VOD.L) announced a strategic partnership agreement with Oman Future Telecommunications in the Sultanate of Oman as part of Vodafone's Partner Markets programme.

Under the non-equity agreement, Vodafone and OFT will work together to roll out a new mobile network and develop a number of new services using the Vodafone brand in Oman.

Vodafone expects development of the new network under Vodafone brand in Oman to begin immediately with commercial launch planned for the second half of 2020.

Fahad Al Busaidi, Managing Director of Itqan Tech Development, which is the leading entity of the 3rd mobile operator consortium - OFT, commented, "We are delighted to start our strategic partnership with Vodafone, as part of our digital transformation journey in Oman. Undoubtedly, the launch of the Vodafone brand in Oman will be the most significant event in the telecoms market over recent years."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd. Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.
Follow RTT